Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: A retrospective single-arm cohort study

Atuhani Burnett, Marie Eve Aubé Lecompte, Nora Trabulsi, Pierre Dubé, Mai Kim Gervais, Bertrand Trilling, Alexis Simon Cloutier, Lucas Sideris

Research output: Contribution to journalJournal articlepeer-review

12 Scopus citations

Abstract

Background: Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for patients with colorectal peritoneal carcinomatosis. However, standardization of HIPEC protocols, including which chemotherapeutic agent to use, is lacking in the literature. Therefore, we sought to report survival outcomes from colorectal cancer patients undergoing CRS/oxaliplatin-based HIPEC at our institution over the last 10 years. Methods: Colorectal PC patients treated with CRS/oxaliplatin-based HIPEC 2004-2015 were included. Demographic, clinical, and oncologic data were abstracted from the medical record. Overall (OS) and disease-free survival (DFS) were calculated using Kaplan-Meier analysis. Univariate/multivariate Cox regression analysis was done. Results: Laparotomy was performed in 113 patients for colorectal PC; 91 completed a curative intent CRS/HIPEC. At 3 and 5 years, OS for the CRS/HIPEC cohort was 75% and 55%, and DFS was 50% and 25%, respectively. On multivariate analysis, incremental increases in peritoneal carcinomatosis index (PCI) were associated with worse OS (p = 0.0001) and DFS (p = 0.0001). Grade III/IV complications were also associated with worse OS. Conclusions: A standardized regimen of CRS and oxaliplatin-based HIPEC for colorectal PC is effective with favorable OS and DFS and acceptable complication rates.

Original languageEnglish
Article number83
JournalWorld Journal of Surgical Oncology
Volume17
Issue number1
DOIs
StatePublished - 15 May 2019
Externally publishedYes

Keywords

  • Colorectal cancer
  • HIPEC
  • Oxaliplatin
  • Peritoneal carcinomatosis

Fingerprint

Dive into the research topics of 'Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: A retrospective single-arm cohort study'. Together they form a unique fingerprint.

Cite this